

118TH CONGRESS  
1ST SESSION

# H. R. 5818

To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.

---

## IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 28, 2023

Mr. SMITH of Nebraska (for himself and Mr. GARAMENDI) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned

---

## A BILL

To amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.

1 *Be it enacted by the Senate and House of Representa-*  
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Medicare IVIG Access  
5 Enhancement Act of 2023”.

1 **SEC. 2. EXPANDING COVERAGE OF THE IN-HOME ADMINIS-**  
2 **TRATION OF INTRAVENOUS IMMUNE GLOB-**  
3 **ULIN UNDER THE MEDICARE PROGRAM.**

4 (a) IN GENERAL.—Section 1861 of the Social Secu-  
5 rity Act (42 U.S.C. 1395x) is amended—

6 (1) in subsection (s)(2)(Z), by inserting “(and,  
7 beginning January 1, 2026, for the treatment of  
8 chronic inflammatory demyelinating polyneuropathy  
9 and multifocal motor neuropathy)” after “primary  
10 immune deficiency diseases”; and

11 (2) in subsection (zz), by inserting “(or, begin-  
12 ning January 1, 2026, with diagnosed chronic in-  
13 flammatory demyelinating polyneuropathy and  
14 multifocal motor neuropathy)” after “primary im-  
15 mune deficiency disease”.

16 (b) AUTHORITY FOR VARIANCE IN PAYMENTS.—Sec-  
17 tion 1842(o)(8) of the Social Security Act (42 U.S.C.  
18 1395u(o)(8)) is amended by inserting “and may vary de-  
19 pending on whether such administration is related to  
20 treatment of a primary immune deficiency disease or the  
21 treatment of chronic inflammatory demyelinating  
22 polyneuropathy or multifocal motor neuropathy (as deter-  
23 mined appropriate by the Secretary through notice and  
24 comment rulemaking)” after “of 2012”.